Real-life-persistence to Antifibrotic Treatments
REPEAT
Real-life-Persistence to Antifibrotic Treatments
1 other identifier
observational
10,646
1 country
1
Brief Summary
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment. Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 10, 2024
CompletedFirst Posted
Study publicly available on registry
July 3, 2024
CompletedStudy Start
First participant enrolled
October 16, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 7, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 7, 2026
CompletedApril 15, 2026
April 1, 2026
1.5 years
June 10, 2024
April 14, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Persistence to antifibrotic (AF) treatment (measured as percentage of patients still treated up to 30 months after AF treatment initiation)
up to 30 months
Secondary Outcomes (10)
AF prevalence in French population
up to 5 years
AF incidence in French population
up to 4 years
Number of AF treated patients split by indication
up to 2 years
Number of patients adherent to AF treatment
up to 30 months
Percentage of the target cumulative dose of treatment received by the patients
up to 30 months
- +5 more secondary outcomes
Study Arms (1)
Patients with a reimbursement of AF treatment
Interventions
Eligibility Criteria
All patients with a reimbursement of AF treatment between 2018 and 2022 will be included for analysis.
You may qualify if:
- All patients with a reimbursement of AF treatment between 2018 and 2022 will be included for analysis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clinityx
Boulogne-Billancourt, 92100, France
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 10, 2024
First Posted
July 3, 2024
Study Start
October 16, 2024
Primary Completion
April 7, 2026
Study Completion
April 7, 2026
Last Updated
April 15, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing